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Background: Increased left ventricular mass index has been shown to be associated
with higher mortality in epidemiologic studies. However, the effect of increased left
ventricular mass index on outcomes in patients undergoing aortic valve replacement
is unknown.
Methods: We studied 473 consecutive patients undergoing elective aortic valve
replacement to assess the influence of left ventricular mass index on outcomes in
patients having this procedure. Echocardiographic left ventricular dimensions were
used to calculate left ventricular mass index (considered increased if >134 g/m2 in
male patients and >110 g/m2 in female patients).
Results: Left ventricular mass index was increased in 24% of patients undergoing
aortic valve replacement. Postprocedural complications (respiratory failure, renal
insufficiency, congestive heart failure, and atrial and ventricular arrhythmias),
length of stay in the intensive care unit, and in-hospital mortality were increased in
patients with increased left ventricular mass index. Multivariable analysis identified
prior valve surgery (odds ratio, 4.3; 95% confidence interval, 1.2-15.7; P = .030),
left ventricular ejection fraction (odds ratio, 1.07; 95% confidence interval, 1.01-
1.14; P = .020), history of hypertension (odds ratio, 8.2; 95% confidence interval,
2.2-30.4; P = .002), history of liver disease (odds ratio, 50.4; 95% confidence inter-
val, 4.2-609.0; P = .002), and increased left ventricular mass index (odds ratio, 38;
95% confidence interval, 9.3-154.1; P < .001) as independent predictors of in-hos-
pital mortality. Furthermore, low output syndrome was identified as the most com-
mon mode of death (36%) after aortic valve replacement in patients with increased
left ventricular mass index.
Conclusions: Increased left ventricular mass index is associated with increased
adverse in-hospital clinical outcomes in patients undergoing aortic valve replace-
ment. Although this finding warrants special modification in perioperative manage-
ment, further studies are needed to address whether outcomes in asymptomatic
patients with aortic valve disease could be improved by earlier aortic valve replace-
ment before a significant increase in left ventricular mass index.
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The chronically increased pressure-volumeoverload in patients with aortic valve diseaseresults in left ventricular (LV) hypertrophyand altered geometry as an adaptive mecha-nism that helps maintain contractile perfor-mance despite markedly abnormal loading
conditions.1,2 LV hypertrophy allows normalization of sys-
tolic wall stress and maintenance of ejection performance as
afterload increases.1,2 Inadequate hypertrophy leads to after-
load mismatch and can result in increased wall stress and
decreased contractile performance.2 Extensive hypertrophy
may result in depressed contractility and reduced pump func-
tion.3 Hypertrophy is associated with various LV diastolic
abnormalities (including abnormal relaxation and distensibil-
ity)4,5 and has been associated with increased morbidity and
mortality in epidemiologic studies.6-9 The implications of
increased LV mass on outcomes in patients undergoing aortic
valve replacement (AVR) are poorly characterized. This study
evaluates the influence of increased LV mass index (LVMI)
on in-hospital outcomes of patients undergoing AVR.
Methods
Study Population
All patients undergoing elective AVR between January 1, 1992,
and December 31, 1997, at the University of Michigan were
prospectively identified through a routinely maintained surgical
database. For the purpose of this analysis, patients were excluded
if they underwent an AVR on an emergency basis, had poor
acoustic windows for adequate echocardiographic assessment,
and/or did not undergo an echocardiogram before the operation.
Echocardiographic Methods
All echocardiograms were performed within 3 months of AVR, as
previously reported.10-12 End-diastolic measurements of LV internal
dimension (LVID, in millimeters), interventricular septal thickness
(IVST, in millimeters), and posterior wall thickness (PWT, in mil-
limeters) were obtained according to the conventions established by
the American Society of Echocardiography.11 Diastolic measure-
ments were used to calculate LVMI by means of the formula
described and validated by Devereux and colleagues10,12 as follows:
LVMI (g/m2) = (1.04 [(IVST + LVID + PWT)3 –
LVID3] – 14 g)/Body surface area
The LVMI was considered as increased if greater than 134 g/m2
in men and greater than 110 g/m2 in women.10-12
Data Collection and Entry
Medical charts were reviewed retrospectively on each patient to
validate prior information and identify missing elements of inter-
est. Data abstracted included patient demographics, symptoms,
comorbidities, physical signs, medications, prior cardiac opera-
tions, predominant valvular lesion and cause, cardiac catheteriza-
tion and echocardiographic data, and surgical data. 
Outcome Measures
Chart review was also used to document in-hospital clinical events,
length of stay, and in-hospital mortality for the study population.
Significant bleeding was defined as a need for transfusion of greater
than 3 units, respiratory failure as a requirement for ventilator sup-
port for greater than 72 hours, renal insufficiency as an increase in
baseline creatinine of greater than 2 mg/dL (in the absence of end-
stage renal failure on dialysis), and hepatic dysfunction as an eleva-
tion of hepatic enzymes of greater than 3 times normal levels. The
modes of death were assigned as described previously.13
Statistical Analysis
Summary statistics are presented as frequencies and percentages,
mean ± standard deviation, or median and interquartile range.
Associations among nominal variables were compared by χ2 tests,
2-sided Fisher exact tests, or Cochran-Mantel-Haenszel χ2 tests
(for a trend within an ordinal category). Continuous univariate pre-
dictors for LVMI and death were tested by t tests or Wilcoxon-
Mann-Whitney tests as appropriate.
For all logistic-regression modeling, a stepwise selection method
was used initially to determine independent predictors of elevated
LVMI and then to determine independent predictors of mortality.
The initial findings were verified or modified by iterative modeling,
testing interactions and quadratic effects. Models were compared by
means of the likelihood ratio test and by the R2 proportion reduction
in likelihood ratio. The entire data set was used; no validation was
performed, although diagnostic routines (eg, Hosmer and Lemeshow
test for lack of fit, change in deviance and residuals, and leverage
indicators) were used on final model selection. Odds ratios (ORs),
95% confidence intervals (95% CI), P values, and the approximate
area under the receiver-operating curve, or c-statistic, were reported.
Post hoc comparisons among the model variables were made with
the standardized regression coefficient. This provided a method to
rank the effect of variables across models.
Propensity Analysis
Because we imposed a dichotomy to LVMI, we sought to balance
the effect of varying LVMI on the outcome of interest by develop-
ing propensity scores from a logistic model predicting normal or
elevated LVMI.14-16 These scores reflect the probability of elevat-
ed LVMI for each patient, given a set of observed covariates. By
stratifying the propensity scores into quintiles, the distributions of
the background covariates predicting either normal or elevated
LVMI should be similar.14-16
First, a predictive model for dichotomized LVMI was generated
by using a set of variables suggestive of an association (P < .20).
Iterative modeling reduced the multivariate model (all P < .05).
Interactions were tested iteratively and retained when suggestive of
an association. This overparameterized model should help mini-
mize the bias in estimating model coefficients and increase the effi-
ciency in determining the model variance.16 The maximum number
or parameters in the model to generate propensity scores was limit-
ed to n1/2 or √473 = 21.17 The predicted probabilities of elevated
LVMI were ranked into quintiles, and the distributions of the model
covariates were compared across LVMI groups. At least 95% of the
comparisons showed no significant association to consider ade-
quate balance within each stratum (P > .05).18
Second, a predictive model for in-hospital mortality was gener-
ated by a set of variables suggestive of an association (P < .20). A
parsimonious model for mortality was developed.
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Third, dummy variables indicating membership in 1 of the 5
quintiles of propensity scores were included in a new set of model-
ing iterations. The final iterations provided the model containing
predictors of clinical relevance, statistical significance, or both. SAS
(SAS Institute, Inc, Cary, NC) software was used for all analyses.
Results
Study Population
Of 509 patients who underwent elective AVR during the
study period, 473 had echocardiographic data available and
were included in this study (mean age, 61.2 ± 14.5 years;
female patients, 61.3%). Patients with and without
increased LVMI were similar with respect to mean age, sex,
and race distribution (Table 1). Baseline demographics and
clinical symptoms and signs were similar, except for a high-
er proportion of patients with increased LVMI presenting
with congestive heart failure and those with normal LVMI
presenting with chest pain (Table 1). Comorbidities and
medical and surgical histories were similar for the 2 groups
of patients (Table 2).
Echocardiographic LVMI Data
Echocardiographic LVMI data are shown in Table 3. The
mean LVMI for men and women were 107.5 ± 45.1 g/m2
and 94.6 ± 40.9 g/m2, respectively. The mean LVMI when
adjusted for differences in sex by dividing LVMI by 134
g/m2 in male patients and 110 g/m2 in female patients were
0.86 ± 0.37 and 0.80 ± 0.34, respectively. An increased
LVMI was present in 24.3% of patients studied (22.4% male
patients and 27.3% female patients, P = .23).
Surgical Data
Surgical data are shown in Table 4. Isolated AVR was per-
formed in 78.5% of patients, aortic and mitral valve replace-
ment, repair, or both in 17.3%, combined aortic arch
replacement with AVR in 4.2%, and concomitant coronary
artery bypass surgery in 30%. The predominant indication
for AVR was aortic stenosis in 54% and aortic regurgitation
in 46% of patients. The mean ischemic time was similar for
patients with or without elevated LVMI.
Outcomes
Clinical events, length of stay, and mortality are shown in
Table 5. Compared with patients with normal LVMI, those
with increased LVMI had a higher association of in-hospital
congestive heart failure, cardiac arrest, bleeding requiring
transfusion, respiratory failure, renal insufficiency, hepatic
dysfunction, ventricular arrhythmias, need for inotropic
support for greater than 48 hours, use of intra-aortic balloon
pump, and sepsis. The incidence of atrial arrhythmias, medi-
astinitis, wound infection, stroke, and reexploration and the
need for a permanent pacemaker were similar in the 2
groups of patients. Median length of stay in the intensive
care unit was longer and in-hospital mortality was signifi-
cantly higher for patients with increased LVMI than those
without increased LVMI. The cumulative percentage of
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Figure 1. Cumulative mortality (%) with increasing LVMI in patients undergoing elective AVR. *LVMI was nor-
malized to adjust for sex differences by dividing LVMI by 110 g/m2 in female patients and 134 g/m2 in male
patients.
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mortality with increasing LVMI is shown in Figure 1. The
proportion of patients who died increased with increasing
deciles of LVMI (Table 6).
Univariate associations to mortality included edema at pre-
sentation, a history of gastrointestinal disease, carotid stenosis,
a history of liver disease, alcoholism, a prior operation for
peripheral vascular occlusive disease, prior valve surgery, his-
tory of hypertension, mitral stenosis, operation involving aor-
tic arch reconstruction, catheterization, and increased LVMI
(all P < .05). Various adverse events were associated with
greater odds of in-hospital mortality: congestive heart failure,
shock, cardiac arrest, pneumonia, mediastinitis, respiratory
failure, renal failure, hepatic dysfunction, sepsis, cerebrovas-
cular accident, transfusion requirement, ventilation, additional
inotropic support, intra-aortic balloon support, or reexplo-
ration (all P < .05). Age greater than 65 years was marginally
associated with mortality; however, this association did not
trend linearly with increasing age. The 373 patients who had
elective aortic valve surgery only had a lower mortality than
all other valve operations or combinations of valve operations
combined (3.8% vs 11.0%, P < .004). Increased pump time
was linearly associated with mortality (P < .001).
In this phase of the analysis, we generated logistic models
for mortality, adding LVMI initially and then the confounders
Surgery for Acquired Cardiovascular Disease Mehta et al
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TABLE 1. Baseline characteristics
Characteristics Total Increased LVMI Normal LVMI P value
No. 473 115 358
Patient demographics
Age, y (mean ± SD [median]) 61.2 ± 14.5 (64) 61.2 ± 14.7 (63.8) 61.2 ± 14.5 (64.0) .99
Male, n (%) 290 (61.3) 65 (56.5) 225 (62.8) .23
White patients, n (%) 343 (79.0) 78 (75.0) 265 (80.3) .25
Clinical symptoms and signs
Syncope, n (%) 60 (12.7) 13 (11.3) 47 (13.1) .61
Angina, n (%) 41 (8.7) 9 (7.8) 32 (8.9) .71
Chest pain, n (%) 230 (48.6) 43 (37.4) 187 (52.2) .006
Congestive heart failure, n (%) 140 (29.6) 51 (44.4) 89 (24.9) <.001
New York Heart Association class ≥3 232 (68.3) 88 (76.5) 235 (65.6) .029
Systolic blood pressure, mm Hg (mean ± SD) 131.1 ± 34.1 131.3 ± 25.2 131 ± 36.5 .92
Diastolic blood pressure, mm Hg (mean ± SD) 70.8 ± 13 66.8 ± 13.3 72 ± 12.7 <.001
Elevated jugular venous pressure, n (%) 36 (7.6) 15 (13.0) 21 (5.9) .012
Bilateral rales >one third of lung fields, n (%) 40 (8.5) 15 (13.0) 25 (7.0) .042
Third heart sound, n (%) 64 (13.5) 28 (24.4) 36 (10.1) <.001
Pedal edema, n (%) 58 (12.3) 21 (18.3) 37 (10.3) .024
TABLE 2. Comorbidities and past medical history
Comorbidities Total Increased LVMI Normal LVMI P value
Hypertension, n (%) 196 (41.4) 49 (42.6) 147 (41.1) .77
Diabetic, n (%) 63 (13.3) 13 (11.3) 50 (14.0) .46
Chronic obstructive pulmonary disease, n (%) 59 (12.5) 16 (13.9) 43 (12) .59
Coronary artery disease, n (%) 141 (29.8) 35 (30.4) 106 (29.6) .87
Elevated cholesterol, n (%) 72 (15.2) 10 (8.7) 62 (17.3) .025
Renal insufficiency, n (%) 19 (4.0) 9 (7.8) 10 (2.8) .017
Liver disease, n (%) 6 (1.3) 4 (3.5) 2 (0.6) .033
Peripheral vascular disease, n (%) 53 (11.2) 10 (8.7) 43 (12.0) .33
Current smokers, n (%) 131 (27.7) 33 (28.7) 98 (27.4) .78
Past medical history
Myocardial infarction, n (%) 43 (9.1) 12 (10.4) 31 (8.7) .56
Stroke, n (%) 50 (10.6) 10 (8.7) 40 (11.2) .45
Coronary angioplasty, n (%) 20 (4.2) 3 (2.6) 17 (4.8) .43
Coronary artery bypass surgery, n (%) 25 (5.3) 5 (4.4) 20 (5.6) .61
Valvular surgery, n (%) 48 (10.2) 16 (13.9) 32 (8.9) .12
Vascular surgery, n (%) 44 (9.3) 11 (9.6) 33 (9.2) .91
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of LVMI to the predictive model. Several of these modifiers
were already in the original model because of an association
with mortality. The additional variables were pulmonary
edema, third heart sound, presence of aortic regurgitation or
aortic stenosis as predominant lesions, and pulse pressure.
The logistic-regression model for mortality including
LVMI revealed a list of variables associated with both mor-
tality and increased LVMI (Table 7). The associations to
mortality were as follows: LVMI (OR, 23.1; 95% CI, 7.2-
73.9; P < .001); history of liver disease (OR, 36.3; 95% CI,
4.2-314.3; P = .001); age greater than 65 years in main and
quadratic terms (OR, 0.80; 95% CI, 0.64-1.00; P = .052; and
OR, 1.002; 95% CI, 1.000-1.004; P = .041, respectively);
prior valve surgery (OR, 3.47; 95% CI, 1.04-11.63; P <
.043); history of hypertension (OR, 5.91; 95% CI, 1.75-
20.02; P = .004); and carotid stenosis (OR, 5.95; 95% CI,
1.42-24.91; P < .014). The fit of the model was good (P =
.82, c-statistic = 0.90) where the predicted number of deaths
had high correspondence with the actual deaths across the
continuum of risk (data not shown).
Propensity Analysis
Propensity scores were generated by means of a logistic-
regression model for elevated LVMI to derive more robust
model estimates of variance. This model included 13 con-
founding variables seen with strong univariate associates (P <
.05), including categoric interactions. Propensity scores were
ranked and classified into quintiles. Within each quintile,
cross-tabulations and Student t tests were run across increased
and normal LVMI classes. Although 13 of the 65 comparisons
had too few counts to compare across classes, only one of the
remaining 52 comparisons failed to balance on the observed
covariates (with P > .05). This indicated that the probability of
elevated or normal LVMI was relatively similar within a quin-
tiled stratum, conditional on the observed covariates.
Last, we regenerated the logistic regression model for
mortality with dummy variables that reflected membership
into each quintile of propensity score. The main effect of
age and the quadratic age, in addition to an indication of
carotid stenosis, were removed from the model. The final
model retained all other covariates, including LVMI and LV
ejection fraction (Table 8). 
After adjustment, this model identified the following asso-
ciations to an increased risk of in-hospital mortality: an
increased LVMI (OR, 37.9; 95% CI, 9.3-154.1; P < .001); a
history of liver disease (OR, 50.4; 95% CI, 4.2-609.0; P =
.001); a history of hypertension (OR, 8.2; 95% CI, 2.2-30.4;
P = .002); LV ejection fraction (OR, 1.07; 95% CI, 1.01-1.14;
P = .020); and prior valve surgery (OR, 4.3; 95% CI, 1.2-
15.7; P = .03). Increased LVMI remained the strongest pre-
dictor of mortality, having more than twice the standardized
estimate than all other covariates (eg, 0.858 vs 0.436 for LV
ejection fraction). Confounders did not reduce or modify
greatly the predictive strength of LVMI. The final model pro-
vided an excellent predictive fit (P = .14, df = 8; c-statistic =
0.90).
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   923
TABLE 3. Echocardiographic data
Echocardiographic data Total Increased LVMI Normal LVMI P value
Left ventricular ejection fraction, 52 ± 11 (56) 46.2 ± 13.6 (50) 54 ± 9.7 (60) <.001
% (mean [median])
Wall-motion abnormalities, % 41 (8.7) 10 (8.7) 31 (8.7) .99
LVMI, female patients (mean ± SD)* 0.86 ± 0.37 1.35 ± 0.30 0.68 ± 0.18 NA
LVMI, male patients (mean ± SD)* 0.80 ± 0.34 1.30 ± 0.29 0.66 ± 0.18 NA
NA, Not applicable.
*LVMI (in grams per square meters) was normalized to adjust for sex differences by dividing LVMI by 110 g/m2 in female patients and 134 g/m2 in male
patients.
TABLE 4. Surgical data
Predominant valvular lesion Total Increased LVMI Normal LVMI P value
Aortic stenosis, n (%) 255 (53.9) 48 (41.7) 207 (57.8) .003
Aortic regurgitation, n (%) 214 (45.2) 67 (58.3) 147 (41.1) <.001
Other surgical data 
Mitral valve surgery, n (%) 82 (17.3) 28 (24.4) 54 (15.1) .022
Coronary artery bypass surgery, n (%) 161 (34.0) 42 (36.5) 119 (33.2) .52
Aortic arch replacement, n (%) 20 (4.2) 5 (4.4) 15 (4.2) .94
Tricuspid valve repair, n (%) 17 (3.6) 5 (4.4) 12 (3.4) .62
Operative ischemic time, 144 ± 59 (140) 150 ± 52 (142) 142 ± 61 (138) .18
min (mean ± SD [median])
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Age and sex dropped out early in model selection. The
sex adjustment inherent in LVMI and the age adjustment in
propensity scores may have accounted for the lack of statis-
tical significance. Mean LV ejection fraction did not differ
between surviving and dead patients, yet it was significant
in predicting death. Other strong effects of confounders to
LVMI, such as congestive heart failure, New York Heart
Association class, third heart sound, predominant aortic
regurgitation, or stenosis, were removed during modeling.
Forty-eight percent of patients with hospital death had at
least 2 of 4 nominal factors (history of liver disease, history
of hypertension, prior valve surgery, and increased LVMI)
versus 4.9% of survivors (P < .001). In testing whether hav-
ing at least 2 of 4 factors was associated with mortality,
94.6% specificity and 35.3% sensitivity was obtained in pre-
dicting in-hospital death after AVR. The probability that an
AVR patient with less than 2 nominal factors survives the
operation (ie, negative predictive value) was 91.1%.
Among the 25 patients who died after AVR, modes of
death are as shown in Table 9. Low output syndrome was
determined as the cause of death in 9 of 25 patients, where-
as 16 patients died of causes other than low output syn-
drome. The LVMI was increased in all 9 patients who died
of low output syndrome (P = .12), whereas no patient with
normal LVMI died of a low cardiac output.
Discussion
Our study identified an increased LVMI as a strong predic-
tor of poor outcomes after elective AVR, specifically
increased in-hospital clinical events, length of stay, and in-
hospital mortality. We found LVMI, as a predictor of mor-
tality, to be highly resistant to confounding by variables that
were directly associated with increased LVMI. Furthermore,
we identified low cardiac output as the most common mode
of death in patients with increased LVMI undergoing AVR.
Previous studies have identified factors that increase oper-
ative morbidity and mortality in patients undergoing AVR,
including advanced age, prior AVR, associated coronary artery
disease, advanced functional class, LV dysfunction, aortic
regurgitation as opposed to aortic stenosis, atrial fibrillation,
and renal insufficiency.19-21 Epidemiologic studies6-9 and
studies in patients with hypertension,22 have identified
increased LVMI as an important marker for increased morbid-
ity and mortality. Our findings confirm the association of poor
outcomes with increased LVMI in patients undergoing AVR.
Surgery for Acquired Cardiovascular Disease Mehta et al
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TABLE 5. Outcomes
Clinical events Total Increased LVMI Normal LVMI P value
Congestive heart failure, n (%) 17 (3.6) 10 (8.7) 7 (2.0) .002
Cardiac arrest, n (%) 18 (3.8) 14 (12.2) 4 (1.1) <.001
Bleeding, n (%) 50 (10.6) 20 (17.4) 30 (8.4) .006
Atrial fibrillation, n (%) 165 (34.9) 49 (42.6) 116 (32.4) .046
Mediastinitis, n (%) 9 (1.9) 2 (1.7) 7 (2.0) .99
Ventricular arrhythmias, n (%) 28 (5.9) 15 (13) 13 (3.6) <.001
Renal failure, n (%) 28 (5.9) 17 (14.8) 11 (3.1) <.001
Respiratory failure, n (%) 37 (7.8) 22 (19.1) 15 (4.2) <.001
Hepatic dysfunction, n (%) 10 (2.1) 7 (6.1) 3 (0.8) .003
Inotropic support >48 hours, n (%) 24 (5.1) 17 (14.8) 7 (2.0) <.001
Intra-aortic balloon counterpulsation, n (%) 10 (2.1) 8 (7.0) 2 (0.6) <.001
Sepsis, n (%) 22 (4.6) 10 (8.7) 12 (3.4) .018
Stroke, n (%) 26 (5.5) 8 (7.0) 18 (5.0) .43
Permanent pacemaker, n (%) 21 (4.4) 8 (7.0) 13 (3.6) .13
Reexploration, n (%) 13 (2.7) 5 (4.3) 8 (2.2) .23
Length of ICU stay, d (median [IQR])* 2 (1-3) 3 (2-8) 2 (1-3) <.001*
In-hospital mortality, n (%) 25 (5.3) 20 (17.4) 5 (1.4) <.001
ICU, Intensive care unit.
*Comparison made on medians, distribution by using Wilcoxon rank sum test.
TABLE 6. Distribution of survivors and mortalities across
levels of LVMI
Percentage 
LVMI midpoint Survivors Mortalities of mortality
0.2 8 1 12.5
0.4 61 0 0
0.6 132 0 0
0.8 109 3 2.8
1.0 69 2 2.9
1.2 36 7 19.4
1.4 13 5 38.5
1.6 9 4 44.4
1.8 7 1 14.3
2.0 4 2 50.0
Sum 448 25
Mehta et al Surgery for Acquired Cardiovascular Disease
TX
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
Our finding is similar to that of the study of Orsinelli and
colleagues,23 who showed that LV hypertrophy (increased
relative LV wall thickness) was associated with greater post-
operative mortality after AVR for aortic stenosis. However,
several differences between our study and that of Orsinelli
and colleagues deserve comment. First, we included all
patients undergoing AVR for a variety of conditions, not just
isolated aortic stenosis. Second, we used LVMI, not relative
LV wall thickness, as a measure of LV hypertrophy. Third,
beyond the increased in-hospital mortality, we showed
increased nonfatal events and length of stay among patients
with an increased LVMI. Finally, we identified low output
syndrome as the most common mode of death.
Several mechanisms may operate in the elevated risk
accompanying an increased LVMI in patients having AVR.
Excessive LV hypertrophy has been shown to be associated
with contractile impairment and pump dysfunction, leading
to congestive heart failure.3,8 Furthermore, heterogeneity in
diastolic function has been reported in patients with aortic
stenosis, varying from abnormal relaxation to reduced dis-
tensibility.4,5,24-27 This effect is similar to that seen in pres-
sure-overload hypertrophy in patients with hypertension.28
Mechanisms underlying this heterogeneity include individ-
ual differences in the severity of muscle hypertrophy, sys-
tolic dysfunction, or both or differences in the severity of
mitral regurgitation and in the level of left atrial pres-
sure.24,25,28 Echocardiographic data on measures of dia-
stolic function were not available in our patients, and on
average, systolic function was decreased in patients with
increased LVMI compared with in those without increased
LVMI (Table 3). Multivariable modeling, controlling for
systolic dysfunction, showed that increased LVMI remained
a highly significant predictor of in-hospital mortality.
Furthermore, the mean LV ejection fraction was relatively
preserved (52% ± 11%) in our study and was directly asso-
ciated with increased mortality in the multivariate model.
This suggests that in patients with normal or near-normal
LV ejection fraction, the greater degree of diastolic dys-
function caused by greater contractility and smaller hearts
may worsen outcomes in such patients. Similarly, systolic
hypertension remained an important independent predictor
of mortality in the multivariate model. A possible explana-
tion could be that for a given degree of LV hypertrophy,
hypertensive patients may have greater diastolic dysfunction
than those without elevated systolic blood pressure.
Aurigemma and colleagues,29 in a study with a small
number of patients undergoing AVR for aortic stenosis,
showed that a subset of these patients has an abnormal intra-
cavitary flow acceleration postoperatively that is often asso-
ciated with distinct LV geometry (small cavity with marked
hypertrophy) and supernormal LV function. This subset had
systemic hypotension and a low cardiac output postopera-
tively, despite normal LV ejection fraction. This occurred in
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TABLE 7. Univariate associations with mortality and model when modeling with variables associated with mortality and
including LVMI and its confounders among patients undergoing elective aortic valve surgery
Univariate Logistic model
Variable Overall (of 473) Deaths (of 25) P value OR 95% CI P value
Increased LVMI (>1) 24.3% 80.0% <.001 23.1 7.2-73.9 <.001
History of liver disease 1.3% 12.0% <.001 36.3 4.2-314.3 .001
Age, y (mean ± SD) 61.2 ± 14.5 62.3 ± 16.6 .73 0.80 0.64-1.00 .052
Quadratic age >65 y 3955 ± 1674 4151 ± 1836 .59 1.002 1.000-1.004 .041
Prior valve surgery 10.1% 28.0% .002 3.5 1.04-11.6 .044
LV ejection fraction (mean ± SD) 52.1 ± 11.3 52.3 ± 9.9 .92 1.06 1.01-1.11 .024
Carotid stenosis 6.8% 16.0% .06 6.0 1.4-24.9 .014
History of hypertension 11.4% 24.0% .042 5.9 1.7-20.0 .004
Intercept: parameter coefficient (SE) –2.9 (3.19)
OR, Odds ratio; CI, confidence interval.
TABLE 8. Final logistic-regression model for mortality
adjusted with propensity scores for the probability of ele-
vated LVMI conditional on observed covariates associated
with LVMI among patients undergoing elective aortic valve
surgery
Variable Odds ratio 95% CI P value
LVMI (mean ± SD) 37.9 9.3-154.1 <.001
History of liver disease 50.4 4.2-609.0 .001
History of hypertension 8.2 2.2-30.4 .002
LV ejection fraction 1.07 1.01-1.14 .020
(mean ± SD)
Prior valve surgery 4.3 1.2-15.7 .030
Intercept (parameter –9.65 (2.22)
coefficient [SE])
Results for the dummy variables reflecting propensity score; strata are not
shown.
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the absence of systolic anterior motion of the mitral valve
leaflet, asymmetric septal hypertrophy causing outflow
obstruction, or both. The authors speculated that the drop in
LV afterload after AVR and concomitant treatment with pos-
itive inotropic agents enhanced intracavitary flow velocity
and exacerbated abnormal ejection dynamics. In our study
the most common mode of death was low output syndrome
(36%), accounting for half of the deaths in patients with
increased LVMI. No patients with a normal LVMI died of a
low cardiac output syndrome. Inotropic drugs and intra-aor-
tic balloon counterpulsation were more frequently used in
the postoperative period in patients with increased LVMI.
The resultant increase in contractility and reduction in after-
load could have contributed to abnormal LV ejection
dynamics and poor outcomes, as observed in the study by
Aurigemma and colleagues.
Some investigators have reported an increase in mortality
when patients require coronary artery bypass surgery in addi-
tion to AVR compared with that seen in patients requiring
AVR alone. In our study the need for concurrent coronary
artery bypass surgery was similar in patients with and with-
out increased LVMI and thus could not have accounted for
the difference in outcomes observed. Abnormalities of coro-
nary flow reserve have been reported in patients with
increased LVMI in the absence of flow-limiting coronary
artery stenosis.30,31 Marcus and colleagues31 showed a reduc-
tion in coronary blood flow velocity during reactive hyper-
emia at the time of operation in patients with severe aortic
stenosis. This aberrance of flow reserve aggravates ischemia
of the left ventricle in addition to that caused by frequent
association of aortic valve disease with coronary artery dis-
ease and the supply and demand mismatch unique to this dis-
ease process and leads to systolic and diastolic LV dysfunc-
tion in the perioperative period.32-34 Thus, the hypertrophied
left ventricle poses a special problem for effective cardiopro-
tection during ischemic arrest, even in a beating heart on
extracorporeal circulation, where the mean perfusion pres-
sures are lower, as observed during low blood pressure in
hypertensive patients who have a hypertrophied heart.35
LV hypertrophy predisposes to the development of car-
diac arrhythmias36-38 and sudden death.9 The propensity for
rhythm disturbances may be exaggerated in the periopera-
tive period as a result of alterations in the metabolic param-
eters and the use of drugs that could potentiate arrhythmias.
We observed an increase in serious ventricular arrhythmias
and a trend toward more atrial arrhythmias in patients with
increased LVMI.
Finally, 2 other factors were identified to be associated
with increased in-hospital mortality in patients undergoing
AVR: repeat valve surgery and liver disease. Prior studies
have shown increased mortality with repeat AVR, and our
finding is consistent with the results of these studies.19-21
The association of liver disease with increased mortality
may be related to associated coagulopathy, increased risk of
infection, volume overload, renal insufficiencies, or overall
poor health status of such patients.
Clinical Implications
This study suggests that patients undergoing elective AVR
who have increased LVMI should have all precautions taken
during ischemic arrest to optimize cardioprotection. Adequate
cardioplegic solution should be delivered for preservation of
the entire myocardium, and retrograde administration
through coronary sinus infusion should be considered.
Coronary artery disease should be aggressively treated to pre-
vent ischemia in the perioperative period. A decrease in after-
load caused by intra-aortic balloon counterpulsation may
worsen the hemodynamic profile of patients with critical aor-
tic stenosis. Thus, its routine use cannot be recommended for
patients undergoing AVR. Careful monitoring for metabolic
parameters should be performed, and any abnormalities
should be promptly corrected to prevent serious arrhythmias.
Hypotension should be expeditiously reversed with volume
resuscitation and use of α-agonists rather than positive
inotropic agents. Congestive heart failure from diastolic dys-
function should be treated by slowing the heart rate (calcium
channel and β-blockers) or converting tachyarrhythmias as
appropriate. All such precautions in patients with increased
LVMI undergoing AVR may help improve their outcomes.
Finally, as noted previously, our findings raise an important
issue as to whether patients with severe aortic valve disease
should have AVR earlier in the course of their disease, when
they are minimally symptomatic or even asymptomatic and
before the development of more severe LV hypertrophy
leads to a greater perioperative risk.39
Limitations of the Study
Although patients were prospectively identified, much of the
data were obtained by means of a chart review, and thus the
analysis has limitations inherent to such studies. Also,
although we identified attributes and outcomes associated
with increased LVMI, causality cannot be proven. Most AVRs
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TABLE 9. Relationship of mode of death to increased LVMI
LVMI
Death Normal Increased Total
Low output syndrome 0 9 9
Other causes* 5 11 16
Total 5 20 25
*Bleeding from coagulopathy (5); recurrent supraventricular and ventricu-
lar tachycardia (3); sepsis caused by mediastinitis-wound infection (2);
thyroid storm caused by amiodarone (1); intracranial bleed (cerebral
aneurysm [1], spontaneous [1]); occipitoparietal infarction (1); sponta-
neous dehiscence of distal aortic graft (1); and acute on chronic liver fail-
ure, sepsis, and renal shutdown (1).
Mehta et al Surgery for Acquired Cardiovascular Disease
TX
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
at our center (>95%) were performed by a single surgeon spe-
cializing in aortic operations. Thus, our findings may not be
generalizable to other centers or surgeons that perform few
AVRs. Our results are not applicable for patients undergoing
emergency AVRs because we excluded them. The LVMI was
estimated by means of M-mode echocardiography, which
may not be valid in the setting of abnormal LV geometry.
Also, the long-term effects of LVMI on outcomes after AVR
cannot be determined from this study. Finally, although no
validation was performed in our study, the consistent results
in modeling with and without adjustment by use of a multi-
variate model and propensity scores reveals the predictive
strength of LVMI to mortality, conditional on observed
covariates. Thus, we believe that analyses at other institutions
or from a regional or national database will validate that
LVMI is an exceptionally important predictor of mortality.
Conclusion
Increased LVMI is associated with increased in-hospital
clinical events, greater length of stay, and increased in-hos-
pital mortality in patients undergoing AVR. This finding
calls for special attention to perioperative management of
such patients. Whether asymptomatic patients with signifi-
cant aortic valve disease and an increased LVMI would ben-
efit from earlier AVR requires further investigation.
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